EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
Emmaus Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026
- Market cap
- $6.03M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2025
Gross margin
93.1%+2.8 pts over 5 years
Operating margin
1.9%+2.0 pts over 5 years
Net margin
-60.2%−66.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -25.2% | -12.2% | -11.7% | +62.0% | |
| Gross profit | -25.0% | -9.8% | -11.1% | +61.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 102.4% | -16.7% | 12.5% | |
| Return on assets | -355.1% | 2.3% | -33.3% | |
| Current ratio | 0.30 | 0.48 | 0.11 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | – | |
| Interest coverage | – | -0.0× | 0.0× | |
| Inventory turnover | – | 0.3× | 0.5× | |
| Capex to revenue | – | 0.1% | 0.0% | |
| Diluted shares | 1M | 49M | 64M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Emmaus Life Sciences generated $10.13M from operations and spent $129.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$10.13M
Used
$129.00K
Capital expenditure$129.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-60.2%
×Asset turnover0.55×
×Equity multiplier-0.38×
=Return on equity, FY202512.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -60.2% | 0.55× | -0.38× | 12.5% |
| FY2024 | -38.7% | 0.57× | -0.56× | 12.4% |
| FY2023 | -12.6% | 0.71× | -1.02× | 9.1% |
| FY2022 | -57.8% | 0.35× | -1.89× | 38.3% |
| FY2021 | -77.4% | 0.35× | -4.37× | 119.9% |
| FY2020 | 5.8% | 0.39× | -7.34× | -16.7% |
| FY2017 | -5535.3% | 0.04× | 1.90× | -408.4% |
| FY2016 | -6981.1% | 0.16× | -0.18× | 201.4% |
| FY2015 | -3376.0% | 0.11× | -0.29× | 102.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$7.49M
- Cash generatingOperating cash flow above zero-$11.00K
- Return on assets improvedROA up on the prior year-18.3% → -31.7%
- Earnings backed by cashOperating cash flow above net income-$11.00K vs -$7.49M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.11 → 0.11
- No dilutionShare count did not rise63M → 64M
- Gross margin improvedGross margin up on the prior year92.79% → 93.12%
- More efficientAsset turnover rose0.47 → 0.53